Aug 21, 2025 • Benzinga
NEUTRAL
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump - PTC Therapeutics ( NASDAQ:PTCT )
PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030. Here is how the structure unfolds under the Adhishthana framework.
Aug 19, 2025 • Benzinga
NEUTRAL
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns - PTC Therapeutics ( NASDAQ:PTCT )
FDA rejects PTC Therapeutics' vatiquinone, citing lack of efficacy for Friedreich's ataxia. After the complete response letter, PTC will discuss the next steps with the FDA. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan ...
Aug 14, 2025 • Benzinga
SOMEWHAT-BULLISH
Behind the Scenes of PTC Therapeutics's Latest Options Trends - PTC Therapeutics ( NASDAQ:PTCT )
High-rolling investors have positioned themselves bullish on PTC Therapeutics PTCT, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Aug 07, 2025 • Motley Fool
NEUTRAL
PTCT Earnings Beat but Sales Drop 4%
Ptc Therapeutics ( NASDAQ:PTCT ) , a biopharmaceutical company specializing in therapies for rare diseases, released its second quarter 2025 earnings on August 7, 2025. The main headline was a beat on both revenue and GAAP earnings per share, despite an overall year-over-year revenue decline.
Aug 07, 2025 • Zacks Commentary
NEUTRAL
PTC Therapeutics ( PTCT ) Reports Q2 Loss, Beats Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 31, 2025 • Zacks Commentary
NEUTRAL
PTC Therapeutics ( PTCT ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.